Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Revenue (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Revenue for 7 consecutive years, with $688000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Revenue rose 10.08% year-over-year to $688000.0, compared with a TTM value of $688000.0 through Mar 2024, down 40.94%, and an annual FY2023 reading of $886000.0, down 61.96% over the prior year.
  • Revenue was $688000.0 for Q2 2023 at Spyre Therapeutics, up from $198000.0 in the prior quarter.
  • Across five years, Revenue topped out at $12.0 million in Q2 2021 and bottomed at $168000.0 in Q4 2022.
  • Average Revenue over 3 years is $3.4 million, with a median of $688000.0 recorded in 2023.
  • The sharpest move saw Revenue crashed 98.55% in 2022, then grew 10.08% in 2023.
  • Year by year, Revenue stood at $3.6 million in 2021, then tumbled by 95.39% to $168000.0 in 2022, then skyrocketed by 309.52% to $688000.0 in 2023.
  • Business Quant data shows Revenue for SYRE at $688000.0 in Q2 2023, $198000.0 in Q1 2023, and $168000.0 in Q4 2022.